BiondVax announced that a phase 3 clinical trial of a generic influenza vaccine showed no statistically significant improvement in influenza infection rates and disease severity compared to placebo.
The company was formed to put into practice the results of 15 years of research by Professor Ruth Arnon (who developed Copaxone) and Dr. Tamar Ben-Yedidi, writes newsru. co. il.
The company's shares on the NASDAQ high-tech stock exchange lost 86% in price. The company says that after 15 years of operation, the company has a significant number of patents, unique experience and the most modern equipment.. Over the years of its existence, about half a billion dollars have been invested in the company.